

BÃ©re Aubry-Rozier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5139949/publications.pdf>

Version: 2024-02-01

33
papers

1,355
citations

623574

14
h-index

414303

32
g-index

36
all docs

36
docs citations

36
times ranked

1403
citing authors

#	ARTICLE	IF	CITATIONS
1	Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. <i>Bone</i> , 2017, 105, 11-17.	1.4	373
2	Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1291-1296.	3.1	270
3	Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 354-358.	1.8	146
4	Spine Trabecular Bone Score Subsequent to Bone Mineral Density Improves Fracture Discrimination in Women. <i>Journal of Clinical Densitometry</i> , 2014, 17, 60-65.	0.5	98
5	Stopping Denosumab. <i>Current Osteoporosis Reports</i> , 2019, 17, 8-15.	1.5	77
6	Clinical Performance of the Updated Trabecular Bone Score (TBS) Algorithm, Which Accounts for the Soft Tissue Thickness: The OsteoLaus Study. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 2229-2237.	3.1	40
7	Impact of lumbar syndesmophyte on bone health as assessed by bone density (BMD) and bone texture (TBS) in men with axial spondyloarthritis. <i>Joint Bone Spine</i> , 2017, 84, 463-466.	0.8	39
8	Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 153-159.	1.1	38
9	Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO. <i>Swiss Medical Weekly</i> , 2017, 147, w14484.	0.8	35
10	Osteogenesis imperfecta: from diagnosis and multidisciplinary treatment to future perspectives. <i>Swiss Medical Weekly</i> , 2016, 146, w14322.	0.8	30
11	Assessing bone impairment in ankylosing spondylitis (AS) using the trabecular bone score (TBS) and high-resolution peripheral quantitative computed tomography (HR-pQCT). <i>Bone</i> , 2019, 122, 8-13.	1.4	26
12	What was your fracture risk evaluated by FRAX® the day before your osteoporotic fracture?. <i>Clinical Rheumatology</i> , 2013, 32, 219-223.	1.0	24
13	Are patients with hypermobile Ehlers-Danlos syndrome or hypermobility spectrum disorder so different?. <i>Rheumatology International</i> , 2021, 41, 1785-1794.	1.5	23
14	Response to Letter: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2112-2112.	1.8	21
15	Cohort Profile: The OsteoLaus study. <i>International Journal of Epidemiology</i> , 2019, 48, 1046-1047g.	0.9	21
16	High Evening Cortisol Level Is Associated With Low TBS and Increased Prevalent Vertebral Fractures: OsteoLaus Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2628-2636.	1.8	13
17	Anakinra compared to prednisone in the treatment of acute CPPD crystal arthritis: A randomized controlled double-blinded pilot study. <i>Joint Bone Spine</i> , 2021, 88, 105088.	0.8	13
18	Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years. <i>Rheumatology</i> , 2020, 59, 1556-1565.	0.9	9

#	ARTICLE	IF	CITATIONS
19	Impact of a fracture liaison service on patient management after an osteoporotic fracture: the CHUV FLS. <i>Swiss Medical Weekly</i> , 2018, 148, w14579.	0.8	9
20	Diurnal Salivary Cortisol in Sarcopenic Postmenopausal Women: The OsteoLaus Cohort. <i>Calcified Tissue International</i> , 2021, 109, 499-509.	1.5	8
21	â€œInflammagingâ€ and bone in the OsteoLaus cohort. <i>Immunity and Ageing</i> , 2020, 17, 5.	1.8	7
22	Reproducibility of Vertebral Fracture Assessment Readings From Dual-energy X-ray Absorptiometry in Both a Population-based and Clinical Cohort: Cohen's and Uniform Kappa. <i>Journal of Clinical Densitometry</i> , 2015, 18, 233-238.	0.5	6
23	Osseous Sarcoidosis Revealed by a Pathologic Fracture and Successfully Treated With Methotrexate and Prednisone. <i>Arthritis and Rheumatology</i> , 2016, 68, 472-472.	2.9	6
24	Comparison of paediatric and adult classification criteria in juvenile idiopathic arthritis during the transition from paediatric to adult care. <i>Joint Bone Spine</i> , 2021, 88, 105047.	0.8	6
25	Osteogenesis imperfecta: towards an individualised interdisciplinary care strategy to improve physical activity and quality of life. <i>Swiss Medical Weekly</i> , 2020, 150, w20285.	0.8	4
26	Morphometric Vertebral Assessments via the Use of Dual X-ray Absorptiometry for the Evaluation of Radiographic Damage in Ankylosing Spondylitis: A Pilot Study. <i>Journal of Clinical Densitometry</i> , 2014, 17, 190-194.	0.5	3
27	Increased Risk of Multiple Spontaneous Vertebral Fractures at Denosumab Discontinuation Must Be Taken Into Account. <i>Journal of Clinical Oncology</i> , 2020, 38, 1641-1642.	0.8	3
28	OP0085â€¦CAN WE AVOID THE LOSS OF BONE MINERAL DENSITY ONE YEAR AFTER DENOSUMAB DISCONTINUATION? THE REOLAUS BONE PROJECT. , 2019, , .		2
29	Hepatosplenomegaly, pneumopathy, bone changes and fronto-temporal dementia: Niemannâ€Pick type B and SQSTM1-associated Pagetâ€™s disease in the same individual. <i>Journal of Bone and Mineral Metabolism</i> , 2019, 37, 378-383.	1.3	1
30	Bisphosphonates as a Firstâ€Line Treatment for Glucocorticoidâ€Induced Osteoporosis: Comment on the Article by Saag et al. <i>Arthritis and Rheumatology</i> , 2019, 71, 1770-1771.	2.9	1
31	Commentary to â€œDenosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trialsâ€ (Galvano et al. <i>J Bone</i>) Tj ETQq11l0.784314 rgBT /		
32	Response to the Letter by Trovas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1087.	1.8	0
33	Denosumab in early-stage breast cancer. <i>Lancet Oncology</i> , The, 2019, 20, e233.	5.1	0